Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

Purpose Obese women with breast cancer have worse prognosis than women with normal body mass index. Endocrine therapy resistance is in part mediated by insulin resistance in obese women with breast cancer. We investigated the tolerability and pharmacokinetics of exemestane in combination with metfor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2013, Vol.71 (1), p.63-72
Hauptverfasser:	Esteva, Francisco J., Moulder, Stacy L., Gonzalez-Angulo, Ana M., Ensor, Joe, Murray, James L., Green, Marjorie C., Koenig, Kimberly B., Lee, Mong-Hong, Hortobagyi, Gabriel N., Yeung, Sai-Ching
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Androstadienes - administration & dosage Androstadienes - adverse effects Androstadienes - therapeutic use Antidiabetics Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Body mass Body mass index Body size Body weight Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Research Chemotherapy Clinical trials Dosage Dose-Response Relationship, Drug Drug Therapy, Combination Endocrine therapy Female Gynecology. Andrology. Obstetrics Humans Insulin Insulin resistance Mammary gland diseases Medical sciences Medicine Medicine & Public Health Metabolic diseases Metastases Metastasis Metformin Metformin - administration & dosage Metformin - adverse effects Metformin - therapeutic use Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Obesity Obesity - physiopathology Oncology Original Article Overweight Overweight - physiopathology Pharmacokinetics Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Post-menopause Postmenopause Receptors Rosiglitazone Thiazolidinediones - administration & dosage Thiazolidinediones - adverse effects Thiazolidinediones - therapeutic use Time Factors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!